| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.081 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Total Income - EUR | 1.811 | 0 | 0 | 456 | 205 | 54 | 0 | - | - | - |
| Total Expenses - EUR | 1.559 | 342 | 476 | 222 | 570 | 118 | 107 | - | - | - |
| Gross Profit/Loss - EUR | 252 | -342 | -476 | 234 | -365 | -64 | -107 | - | - | - |
| Net Profit/Loss - EUR | 252 | -342 | -476 | 234 | -365 | -64 | -107 | - | - | - |
| Employees | 0 | 0 | 1 | 0 | 0 | 0 | 0 | - | - | - |
Check the financial reports for the company - Novaline Pharmex Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 115 | 23 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Current Assets | 3.597 | 3.753 | 8.652 | 7.969 | 5.063 | 4.935 | 4.844 | - | - | - |
| Inventories | 0 | 0 | 4.776 | 4.688 | 4.597 | 4.510 | 4.410 | - | - | - |
| Receivables | 232 | 247 | 264 | 272 | 273 | 270 | 264 | - | - | - |
| Cash | 3.366 | 3.505 | 3.612 | 3.008 | 193 | 155 | 169 | - | - | - |
| Shareholders Funds | 3.132 | 2.758 | 2.236 | 2.429 | 2.017 | 1.915 | 1.765 | - | - | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | - | - | - |
| Debts | 580 | 1.017 | 6.416 | 5.539 | 3.046 | 3.021 | 3.079 | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4791 - 4791" | |||||||||
| CAEN Financial Year |
4791
|
|||||||||
Comments - Novaline Pharmex Srl